Compared to THC, CBD shows a very low affinity for endogenous cannabinoid receptors CB1 and CB2 [5] and actually seems to antagonize the CB1 receptor by allosteri CBD is the first cannabis-based medicine approved by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as an add-on treatment for two rare and severe forms of childhood epilepsies: Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS) [13]. Here, CNR1 is linked to Dravet syndrome.